GRACE

cancergrace.org

 

ASCO Lung Review 2022
14:26

GRACE

The Need for Molecular Testing to Identify Targets in mNSCLC

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 103 views
  • September 6, 2022
  • 1
12:38

GRACE

IO Alone vs. IO + Chemo for NSCLC Pts w/PD-L1≥50%

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 258 views
  • September 6, 2022
07:22

GRACE

Chemo/IO vs. IO vs. Chemo for KRAS-Mutated NSCLC

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 395 views
  • September 6, 2022
  • 2
07:37

GRACE

Pembrolizumab/Ramucirumab vs. Standard 2L Treatment After Chemo and IO for Advanced NSCLC

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 394 views
  • September 6, 2022
  • 2
09:17

GRACE

Amivantamab/Lazertinib for EGFRm+ NSCLC Acquired Resistance

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 15 views
  • September 6, 2022
07:11

GRACE

EGFRm+ NSCLC: Should We Treat With Durvalumab?

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 8 views
  • September 6, 2022
05:29

GRACE

Patritumab Deruxtecan: Use in Previously Treated NSCLC Without Mutations

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 9 views
  • September 6, 2022
04:28

GRACE

SKYSCRAPER-2 Trial: Anti-“TIGIT” IO + Chemo/IO for ES-SCLC

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 186 views
  • September 6, 2022
07:56

GRACE

CheckMate 816: Combining Chemo and Opdivo in Stage 1B-3A NSCLC

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 537 views
  • September 6, 2022
  • 3
12:08

GRACE

Adagrasib for Previously Treated KRAS G12C+ NSCLC

FEATURING Jack West, Jarushka Naidoo, Gilberto Lopes
  • 29 views
  • September 6, 2022
  • 1